A cluster of inflammatory breast cancer (IBC) in an office setting: Additional evidence of the importance of environmental factors in IBC etiology

Oncology Reports

Volumn 24, Issue 5, 2010, Pages 1277-1284

  Duke, Tina J ^a   Jahed, Nasreen C ^b   Veneroso, Carmela C ^b   Da Roza, Ricardo ^c   Johnson, Owen ^c   Hoffman, Daniel ^b   Barsky, Sanford H ^c   Levine, Paul H ^b  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Environmental factors; Hormone replacement therapy; Inflammatory breast cancer; Oral contraceptives

Indexed keywords

ANASTROZOLE; CARBON DIOXIDE; CARBON MONOXIDE; CEFADROXIL; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; HERBICIDE; METHOTREXATE; PACLITAXEL; PESTICIDE; POLYURETHAN; RIFAMPICIN; TAMOXIFEN;

AIR QUALITY; ARTICLE; BREAST BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DERMATITIS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FAMILY HISTORY; FEMALE; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INFLAMMATORY BREAST CANCER; MALE; MAMMOGRAPHY; MASTITIS; MEDICAL HISTORY; METASTASIS; MULTIPLE CYCLE TREATMENT; OBESITY; OFFICE WORKER; ORAL CONTRACEPTION; PLEURA EFFUSION; PREGNANCY; PRIORITY JOURNAL; RADIATION EXPOSURE; RISK FACTOR; WATER QUALITY;

AGE FACTORS; CALIFORNIA; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; ENVIRONMENT; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MIDDLE AGED; OCCUPATIONAL EXPOSURE; RISK FACTORS;

EID: 78149310689     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000983     Document Type: Article

References (42)

1. Hance KW, Anderson WF, Devesa SS, Young HA and Levine PH: Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97: 966-975, 2005.
2. Levine PH, Steinhorn SC, Ries LG and Aron JL: Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst 74: 291-297, 1985.
3. Chang S, Parker SL, Pham T, Buzdar AU and Hursting SD: Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 82: 2366-2372, 1998.
4. Wingo PA, Jamison PM, Young JL and Gargiullo P: Population-based statistics for women diagnosed with inflammatory breast cancer (United States). Cancer Causes Control 15: 321-328, 2004. (Pubitemid 38988041)
5. Williams CKO, Olopade OI and Falkson CI: Breast cancer in women of African descent. Springer, Dordrecht pp91-188, 2006.
6. Mourali N, Muenz LR, Tabbane F, Belhassen S, Bahi J and Levine PH: Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer 46: 2741-2746, 1980. (Pubitemid 11210246)
7. Demers A, Ayotte P, Brisson J, Dodin S, Robert J and Dewailly E: Risk and aggressiveness of breast cancer in relation to plasma organochlorine concentrations. Cancer Epidemiol Biomarkers Prev 9: 161-166, 2000. (Pubitemid 30111938)
8. Chie WC, Hsieh C, Newcomb PA, et al: Age at any full-term pregnancy and breast cancer risk. Am J Epidemiol 151: 715-722, 2000.
9. Veneroso C, Siegel R and Levine PH: Early age at first childbirth associated with advanced tumor grade in breast cancer. Cancer Detect Prev 32: 215-223, 2008.
10. Alpaugh ML, Tomlinson JS, Shao ZM and Barsky SH: A novel human xenograft model of inflammatory breast cancer. Cancer Res 59: 5079-5084, 1999. (Pubitemid 29503962)
11. Tomlinson JS, Alpaugh ML and Barsky SH: An intact overexpressed E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res 61: 5231-5241, 2001.
12. Alpaugh ML, Tomlinson JS, Kasraeian S and Barsky SH: Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene 21: 3631-3643, 2002. (Pubitemid 34587695)
13. Alpaugh ML, Tomlinson JS, Ye Y and Barsky SH: Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol 161: 619-628, 2002.
14. American Society of Heating and Refrigerating, and Air Conditioning Engineers (ASHRAE). Ventilation for acceptable indoor air quality. Standard 62, 1999. http://www.ashrae.org.
15. Rothenberg RB, Steinberg KK and Thacker SB: The public health importance of clusters: a note from the Centers for Disease Control. Am J Epidemiol 132: S3-S5, 1990.
16. Creech JL Jr and Johnson MN: Angiosarcoma of liver in the manufacture of polyvinyl chloride. J Occup Med 16: 150-151, 1974.
17. Chang S, Buzdar AU and Hursting SD: Inflammatory breast cancer and body mass index. J Clin Oncol 16: 3731-3735, 1998.
18. McElroy JA, Egan KM, Titus-Ernstoff L, et al: Occupational exposure to electromagnetic field and breast cancer risk in a large, population-based, case-control study in the United States. J Occup Environ Med/American College of Occupational and Environmental Medicine 49: 266-274, 2007.
19. Floderus B, Stenlund C and Persson T: Occupational magnetic field exposure and site-specific cancer incidence: a Swedish cohort study. Cancer Causes Control 10: 323-332, 1999.
20. Kliukiene J, Tynes T, Martinsen JI, Blaasaas KG and Andersen A: Incidence of breast cancer in a Norwegian cohort of women with potential workplace exposure to 50 Hz magnetic fields. Am J Ind Med 36: 147-154, 1999.
21. Kliukiene J, Tynes T and Andersen A: Follow-up of radio and telegraph operators with exposure to electromagnetic fields and risk of breast cancer. Eur J Cancer Prev 12: 301-307, 2003.
22. Labreche F, Goldberg MS, Valois MF, et al: Occupational exposures to extremely low frequency magnetic fields and postmenopausal breast cancer. Am J Ind Med 44: 643-652, 2003.
23. Kliukiene J, Tynes T and Andersen A: Residential and occupational exposures to 50-Hz magnetic fields and breast cancer in women: a population-based study. Am J Epidemiol 159: 852-861, 2004.
24. Forssen UM, Rutqvist LE, Ahlbom A and Feychting M: Occupational magnetic fields and female breast cancer: a case-control study using Swedish population registers and new exposure data. Am J Epidemiol 161: 250-259, 2005. (Pubitemid 40223513)
25. NIOSH Hazard review carbonless copy paper. DHHS (NIOSH) Publication No. 2001-107, 2000. http://www.cdc.gov/niosh/pdfs/01-107.pdf.
26. Hansen J and Olsen JH: Formaldehyde and cancer morbidity among male employees in Denmark. Cancer Causes Control 6: 354-360, 1995.
27. Rosner D and Lane WW: Oral contraceptive use has no adverse effect on the prognosis of breast cancer. Cancer 57: 591-596, 1986.
28. Greenberg ER, Vessey MP, McPherson K, Doll R and Yeates D: Body size and survival in premenopausal breast cancer. Br J Cancer 51: 691-697, 1985.
29. Mohle-Boetani JC, Grosser S, Whittemore AS, Malec M, Kampert JB and Paffenbarger RS Jr: Body size, reproductive factors, and breast cancer survival. Prev Med 17: 634-642, 1988.
30. Rosner D, Lane WW and Perez Brett R: Influence of oral contraceptives on the prognosis of breast cancer in young women. Cancer 55: 1556-1562, 1985. (Pubitemid 15140694)
31. Rosner DH, Joy JV and Lane WW: Oral contraceptives and prognosis of breast cancer in women aged 35 to 50. J Surg Oncol 30: 52-59, 1985.
32. Sauerbrei W, Blettner M, Schmoor C, Bojar H and Schumacher M: The effect of oral contraceptive use on the prognosis of node positive breast cancer patients. German Breast Cancer Study Group. Eur J Cancer 34: 1348-1351, 1998.
33. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 347: 1713-1727, 1996.
34. Schonborn I, Nischan P and Ebeling K: Oral contraceptive use and the prognosis of breast cancer. Breast Cancer Res Treat 30: 283-292, 1994.
35. Brinton LA, Daling JR, Liff JM, et al: Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 87: 827-835, 1995.
36. Kay CR and Hannaford PC: Breast cancer and the pill-a further report from the Royal College of General Practitioners' oral contraception study. Br J Cancer 58: 675-680, 1988.
37. Olsson H, Borg A, Ferno M, Moller TR and Ranstam J: Early oral contraceptive use and premenopausal breast cancer - a review of studies performed in southern Sweden. Cancer Detect Prev 15: 265-271, 1991.
38. Gerstman BB, Gross TP, Kennedy DL, Bennett RC, Tomita DK and Stadel BV: Trends in the content and use of oral contraceptives in the United States, 1964-88. Am J Public Health 81: 90-96, 1991.
39. Davidson NE: Is hormone replacement therapy a risk? Sci Am 275: 101, 1996.
40. Johnson-Thompson MC and Guthrie J: Ongoing research to identify environmental risk factors in breast carcinoma. Cancer 88: 1224-1229, 2000.
41. Kettles MK, Browning SR, Prince TS and Horstman SW: Triazine herbicide exposure and breast cancer incidence: an ecologic study of Kentucky counties. Environ Health Perspect 105: 1222-1227, 1997.
42. Kase LM: Why community cancer clusters are often ignored. Sci Am 275: 85-86, 1996.